Skip to main content

This journal is devoted to timely reviews of experimental and clinical studies in the field of endocrine, metabolic, and immune disorders. Specific emphasis is placed on humoral and cellular targets for natural, synthetic, and genetically engineered drugs that enhance or impair endocrine, metabolic, and immune parameters and functions. Topics related to the neuroendocrine-immune axis are given special emphasis in view of the growing interest in stress-related, inflammatory, autoimmune, and degenerative disorders.

Publisher: Bentham Science Publishers

Volume 11, Number 4, December 2011

Articles

The Sphingolipid Rheostat: A Potential Target for Improving Pancreatic Islet Survival and Function
pp. 262-272(11)
Authors: F. Jessup, Claire; S. Bonder, Claudine; M. Pitson, Stuart; Toby H. Coates, P.

Favourites:
ADD

The Role of PPARβ/δ in the Management of Metabolic Syndrome and its Associated Cardiovascular Complications
pp. 273-284(12)
Authors: Benetti, Elisa; S.A. Patel, Nimesh; Collino, Massimo

Favourites:
ADD

Ovulation, Implantation and Placentation in Females with Obesity and Metabolic Disorders: Life in the Balance
pp. 285-301(17)
Authors: Gonzalez-Bulnes, Antonio; Pallares, Pilar; Ovilo, Cristina

Favourites:
ADD

FGF10 and FGF21 as Regulators in Adipocyte Development and Metabolism
pp. 302-309(8)
Authors: Ohta, Hiroya; Konishi, Morichika; Itoh, Nobuyuki

Favourites:
ADD

Poly (ADP-Ribose) Polymerase-1 (PARP-1) as Immune Regulator
pp. 326-333(8)
Authors: Laudisi, Federica; Sambucci, Manolo; Pioli, Claudio

Favourites:
ADD

The Regulation of FoxP3-Expressing Regulatory T Cells
pp. 334-346(13)
Authors: Haque, Rizwanul; Lei, Fengyang; Xiong, Xiaofang; Song, Jianxun

Favourites:
ADD

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more